“AP402 targets p95HER2, a truncated form of HER2 present in 30-40% of HER2-positive cancers, which is associated with exceptionally poor prognosis, and not addressable by conventional anti-HER2 therapies,” said Dr. Jeng Her, Ph.D., Founder and Chief Executive Officer of AP Biosciences. “AP402 represents the only T-cell engager in human trials which bridges activated T cells and p95HER2-expressing cancer cells in the tumor – a differentiated mechanism that could deliver a powerful immune response while minimizing systemic toxicity. AP402 thus offers promise as a potential therapeutic option for patients with difficult-to-treat cancers that could enhance efficacy and safety where other treatments fall short.”